Introduction
Leishmania (Leishmania) infantum chagasi is the etiological agent of zoonotic visceral Leishmaniasis, an important reemergent canide zoonose worldwide [1] .
The elimination of seropositive dogs, vector control surround peridomestic environment and systematic treatment of human cases is recommended in Brazil as the current strategy for managing the disease control [1] . In the past 5 years more than 160,000 seropositive dogs have been eliminated in Brazil [2] but it is not universally acceptable, mainly due to ethical reasons [3] , its low impact in situation of endemic transmission [4] and partially because of the resistance by dog owners to acquiesce in culling their infected pets [5, 6] .
The development of a protective vaccine against zoonotic visceral leishmaniasis has been recommended by WHO as important tool in the control of canine visceral Leishmaniasis (CVL) and also for an effective eradication of diseases [7, 8] . Several candidates for canine vaccines against L. (L.) infantum chagasi infection have been proposed and include from live/killed Leishmania parasites (first-generation) to purified Leishmania antigens or live recombinant bacteria expressing Leishmania antigens (second generation) as well as antigen-encoding DNA plasmids (third generations) [9] .
The Leishmune ® , a second-generation vaccine, have been recently licensed in Brazil and become commercially available. It is the first registered vaccine against CVL composed of purified fraction named fucose mannose ligand (FML), isolated from L. donovani promastigotes and uses saponin as adjuvant [10, 11] . This formulation proved to be safe protective and highly immunogenic for dogs [12, 13] . These Phase III trials reported the efficacy of Leishmune ® with protection ranging from 92 to 95%, highlighting the long-lasting and strong immunoprophylactic effect against CVL. Leishmune ® immunogenicity have been reported by its ability to trigger a specific humoral and a potent cellular immune response, as vaccines presented, even 3.5 years after vaccination high anti-FML seropositivity besides positive intradermal reactions [13] . Additionally, it has been stated that Leishmune ® vaccines showed significant increase percentage of circulating CD8 + T-cells as expected for QuilA saponin vaccines. More recently, it has been reported the immunotherapeutic potential of Leishmune ® on CVL, using a new formulation with increased adjuvant concentration have demonstrate that treated animals have the ability to up-regulate the frequency of CD4 + T-cells following Leishmania-specific lymphoproliferation assay in vitro, highlighting the potential of Leishmune ® in eliciting a potent cellular immune response [14] .
Although some encouraging results have been reported by the use of purified fractions from purified Leishmania extracts [11, 12, 15] , the use of vaccines prepared from whole parasites antigens extracts still remain a reliable perspective considering their broad spectrum of antigenicity, cost and safety, and a number of such vaccines have been tested [16, 17] .
Phase I and II clinical trials have demonstrated enhanced in vitro lymphocyte proliferation and significant protection against infection with Leishmania in Brazilian dogs that had received merthiolated ultrasound-disrupted Leishmania promastigotes of together with Bacillus Calmete-guérin (BCG) as adjuvant. Moreover, strong cellular proliferation to soluble Leishmania antigens has also been reported in dogs vaccinated with autoclaved Leishmania promastigotes also using BCG as adjuvant [18] . More recently, it has been reported that a killed Leishmania vaccine with saponin adjuvant elicited a strong antigenicity related to the increase humoral immune response together with outstanding upregulation of CD8 + T-lymphocytes and antigen-specific CD8 + T-cell response [19] .
Despite immunoprophylaxis of CVL has become an important control strategy and protective immunity have been reported following the use of whole parasites antigens extracts as well as purified Leishmania antigens, the precise immunological events triggered by these immunobiological tools still remains to be elucidated. It is important to mention that most previous studies did not report details on the immunological status of canine vaccines, probably due to the lack of specific reagents and standardized protocol to investigate the canine immune response. Aiming to further focus on this issue, herein, we have performed a detailed flow cytometry study in order to characterize the kinetic of changes in phenotypic features of peripheral blood leukocytes triggered by Leishvaccine and Leishmune ® as the prototypes of first and second-generation vaccines against CVL, focusing on both innate and adaptive immune response, using a paired and unified experimental vaccination regimen.
Our results demonstrated that Leishvaccine and Leishmune ® vaccines lead to distinct impact in peripheral blood leukocytes associated with the innate and the adaptive immune response. In particular, Leishvaccine was associated with a mixed cellular and humoral immune response, whereas Leishmune ® showed to trigger a more selective cellular immune response. We hypothesized that both the antigenic nature and the adjuvant employed on each vaccination regimen represent the major key for the differences observed between Leishvaccine and Leishmune ® vaccines.
Materials and methods

Animals
Twenty-four healthy German Shepherd dogs, 16 males and 8 females, age ranging from 18 to 60 months, were maintained at the kennel of Polícia Militar de Minas Gerais, Brazil during the entire experimental procedures. Prior to the inclusion in this study, all animals were treated for intestinal helminthic infections and immunized against parvovirosis, leptospirosis, distemper, parainfluenza and hepatitis. All animals received drinking water and a balanced feed given ad libitum and were maintained in quarantine before the inclusion in the study. The dogs included in this study were selected based on their negative serological results in the enzyme-linked immunosorbent assay (ELISA, Biomanguinhos, FIOCRUZ, RJ, Brazil) used as a reference standard test for the diagnosis of CVL.
All procedures in this study were according to the guidelines set by the Brazilian Animal Experimental College (COBEA). This study was approved by the Ethical Committee for the use of Experimental Animals (CETEA) of the Universidade Federal de Minas Gerais, Brazil.
Vaccination
Dogs were divided into two groups named Leishvaccine and Leishmune ® with twelve animals each. Leishvaccine consisted of Leishmania (L.) amazonensis (strain IFLA/BR/1967/PH8) antigenic preparation obtained as described by Mayrink et al. [18] using BCG (Fundação Ataulfo de Paiva, RJ, Brazil) as adjuvant. The Leishmune ® consisted of Leishmania donovani purified fucose manose ligand (FML), uses saponin as adjuvant and was commercially obtained from FortDodge ® manufacturer. Dogs in the Leishvaccine group were immunized throughout a complete vaccination regimen that included three subcutaneous doses of the vaccine with an interval of 21 days between each. The first dose corresponded to 0.6 ml of Leishvaccine (360 g of protein) plus 0.4 ml of BCG (400 g of protein) as adjuvant. The second dose corresponded to 0.6 ml of Leishvaccine (360 g of protein) plus 0.3 ml of BCG (300 g of protein) as adjuvant. The third dose corresponded to 0.6 ml of Leishvaccine (360 g of protein) plus 0.2 ml of BCG (200 g of protein) as adjuvant.
Dogs in the Leishmune ® were submitted to a complete vaccination regimen as recommended by the manufacturer (FortDodge ® , Campinas, SP, Brazil), which included three subcutaneous doses of 1.0 ml of vaccine with an interval of 21 days between each dose.
Blood samples
Whole EDTA blood samples were collect at four consecutive periods including: before vaccination and 1 week after the 1st, 2nd and 3rd dose of each vaccine, corresponding to T0, T1, T2 and T3, respectively.
Samples constituted of 5 ml of canine whole peripheral blood using EDTA as the anticoagulant (final concentration of 1 mg/ml) collected by trained professional at the kennel of the 4
• Cia da Polícia Militar de Minas Gerais, PMMG, Minas Gerais, Brazil. All samples were maintained at room temperature up to 12 h prior to processing.
Complete hemogram was performed by conventional techniques using an automated blood cell analyzer (ADVIA ® 60, Bayer HealthCare, Tarrytown, NY, USA).
Monoclonal antibodies
A range of cell surface markers that define major and minor canine leukocytes subpopulations were used, including anti-canine CD3-RPE 1:10 (mouse IgG1, clone CA17.2A12), anti-canine CD4-FITC or RPE 1:320 (rat IgG2a, clone YKIX302.9), anti-canine CD5-FITC 1:160 (rat IgG2a, clone YKIX322.3), anti-canine CD8-FITC or RPE 1:40 (rat IgG1, clone YCATE55.9), anti-canine B-cell-RPE 1:160 (mouse IgG1, clone CA2.1D6), anti-human CD14-PE-Cy5 1:40 (mouse IgG2a, clone TuK4), all purchased from Serotec (Oxford, UK).
Aiming to further characterize the activation status of canine peripheral blood leukocytes, a set of cell surface markers were analyzed using anti-mouse MHCI-FITC 1:20 (mouse IgG2b, clone 2G5), anti-canine MHCII-FITC 1:80 (rat IgG2a, clone YKIX334.2), anti-human CD18-RPE 1:6 (rat IgG2b, clone YFC118.3) and anti-human CD32-FITC 1:6 (mouse IgG1, clone AT10), all purchased from Serotec (Oxford, UK). Although virtually almost all nucleated cells express MHCI [20] , canine granulocytes were weakly labeled with anti-MHCI 2G5 monoclonal antibody. In contrast with other species, MHCII molecule is expressed by all canine peripheral blood mononuclear cells [20] , with no reference to expression by canine granulocytes. A small percentage of neutrophils express MHCI and MHCII and may reflect an antigenic priming-immunological event as previously reported for canine lymphocytes [21] . CD32 is the low affinity receptor for aggregated IgG (Fc␥RII), constitutively expressed on granulocytes, monocyte and B-cells. CD32 mediates endocytosis, cytotoxicity and immunomodulation [22] . Two major subclasses of FC␥RII have been described in humans Fc␥RIIa and Fc␥RIIb [23] . In dog, a single report has addressed the analysis of CD32 expression by peripheral blood granulocytes [24] . Although Lilliehöök et al. [24] have reported that anti-CD32 antibodies label percoll-purified neutrophils but not percoll-purified eosinophils, a small percentage of canine unpurified neutrophils and eosinophils express CD32. The glycoprotein CD18 is an adhesion molecule of the complex LFA-1, ICAM-1 ligand crucial for leukocytes' ability to bind on the endothelial cells and further transmigration into the extravascular tissue. CD18 is virtually expressed by all circulating canine granulocytes [24] .
Immunophenotyping of canine whole blood leukocytes
Immunophenotyping analyses of canine peripheral blood through flow cytometry were carried out as follow: in 12 mm × 75 mm polystyrene tubes, 30 l of fresh whole blood were incubated at room temperature (RT) for 30 min in the dark in the presence of 30 l of fluorochrome-labeled anti-canine cell surface marker monoclonal antibodies (mAbs) previously diluted in PBS-0.5%BSA (phosphate buffered saline 0.15 M, pH 7.2 supplemented with 0.5% of bovine seric albumin and 0.1% of sodium azide). After incubation, the erythrocytes were lysed by adding 3 ml of lysis solution (FACS brand lysing solution; Becton Dickinson San Diego, CA, USA) followed by incubation for 10 min at RT. Canine whole blood leukocytes were then washed twice with 2 ml of PBS (phosphate buffered saline 0.15 M, pH 7.2) and centrifuged at 400 g for 10 min at RT. After the washing procedures, labeled cells were then fixed for 30 min at RT, with 200 l of FACS FIX solution (10.0 g/l paraformaldehyde; 10.2 g/l sodium cacodylate and 6.65 g/l sodium chloride, pH 7.2) before analysis in the cytometer. The stained cells were stored at 4-8
• C up to 24 h before cytofluorometric analysis. Each assay included an internal control for autofluorescence in which the cells were incubated in the presence of PBS-0.5%BSA.
Flow cytometry data storage and analysis
Flow cytometric measurements were performed on a FACScan instrument (Becton Dickinson, Moutain View, CA) interfaced to an apple G3 FACStation. The Cell-Quest software package was used in both data acquisition and analysis. A total of 10,000 events were acquired for each preparation. Canine whole blood leukocytes were first identified on the basis of their specific forward (FSC) and side (SSC) lightscatter properties. Following FSC and SSC gain adjustments; the lymphocytes were detected based on their characteristic FSC versus SSC gain distribution.
The neutrophils and lymphocytes and were selected based on their characteristic FSC versus SSC gain distribution and their phenotypic features analyzed on dual color graphs to evaluate their fluorescence spectra for FITC and R-PE on FL1 × FL2 dot plots.
Eosinophil gating strategy was essentially based on their autofluorescence using non-related FL-3 channel versus FSC. A specific scatter gate using anti-CD14 TC versus SSC dot plot combination was performed for selective analysis of monocytes identified as SSC Low CD14 High cells. The results were expressed as percentage of positive cells within the selected gate, for cell surface markers presenting bimodal distribution and the results expressed as percentage of gated cells. For this purpose, a marker was set on the internal control for unspecific binding, in order to confine over 98% of the unlabeled cells. This marker was used in all data analysis for a given sample to determine the percentage of positive cells. 
Statistical analysis
Statistical analysis was performed using the GraphPad Prism 4.03 software package (San Diego, CA, USA). Considering the nonparametric nature of all data sets, the Wilcoxon matched pairs test was used to access significant differences on the phenotypic features during vaccination protocol by comparing for each immunobiological used the post-vaccination timing points (T1, T2 and T3) with the starting point (T0). Spearman's rank correlation was also used to evaluate associations between specific phenotypic features. In all cases, the differences were considered significant when the probabilities of equality, p-values, were p < 0.05.
Results
Vaccinated dogs did not display any significant changes in their hematological profile following Leishvaccine and Leishmune ® vaccination regimens
Aiming to characterize the impact of the Leishvaccine and Leishmune ® on major hematological features, whole EDTA blood samples were collect before and after the 1st, 2nd and T0  T1  T2  T3  T0  T1  T2  T3 White blood cells a 12.5 ± 1.9 13.5 ± 2.3 13.9 ± 2.6 14.4 ± 3.7 13.7 ± 2.6 15.0 ± 3.1 15.1 ± 3.8 15.6 ± 3.2 Granulocytes a 4.6 ± 1.9
5.6 ± 2.1 5.2 ± 1.8 6.0 ± 1.8 5.0 ± 1.8 6.6 ± 2.5 6.6 ± 2.7 6.2 ± 1.8 Monocytes a 3.4 ± 0.8 3.6 ± 0.7 3.4 ± 0.8 3.7 ± 1.4 3.8 ± 0.7 3.9 ± 0.9 3.6 ± 1.0 4.2 ± 1.2 Lymphocytes Down regulation of CD32 parallel with lower CD18 expression was also the hallmark of the phenotypic changes on neutrophils during the entire immunization procedure (T1, T2 and T3) with either Leishvaccine or Leishmune ® ( Fig. 1 , lower left and right panels). On the other hand, persistent up regulation of MHCII was observed throughout the vaccination regimen at T1, T2 and T3, despite the immunogenic tool used (Fig. 1, upper left and right panels) .
Together, our data demonstrated that both immunobiological tools triggered an overall similar phenotypic change on circulating neutrophils following the vaccination regimen.
Leishvaccine triggered selective phenotypic changes on circulating eosinophils, with later input on monocytes, whereas Leishmune ® vaccines display early and persistent changes monocytes with no phenotypic changes on circulating eosinophil Kinetic analysis of phenotypic changes in circulating eosinophils and monocytes was performed following vaccination regimen with Leishvaccine or Leishmune ® . Our data demonstrated that only dogs immunized with Leishvaccine display changes in eosinophil phenotypic features, with down-regulation of CD32 + cells at T2 and T3 and upregulation of CD18 expression at T1 and T2 ( (Fig. 2, upper panels) .
Analysis of phenotypic features of circulating monocytes revealed down-regulation of MHCI following both vaccination regimen at T2 and T3 with selective earlier impact in dogs vaccinated with Leishmune ® as observed at T1 (Fig. 3,  top panels) . No significant differences were observed in the percentage of MHCII + and CD32 + monocytes throughout the vaccination regimen, regardless the immunobiological tool (Fig. 2) . Punctual down-regulation of CD18 expression by monocytes was observed at T3 following immunization with Leishvaccine (Fig. 3, left lower panel) .
Leishvaccine sponsored a mixed profile associated with major phenotypic changes in CD4 + T and B-lymphocytes, whereas Leishmune ® promoted a selective T-cell dependent profile particularly associated with up-regulation of CD8 + T-cells Analysis of the adaptive immunity compartment revealed that while Leishvaccine sponsored a mixed profile, associated with phenotypic changes of T and B-lymphocytes, Leishmune ® vaccination was typically associated a T-cell dependent immunity.
Downregulation of circulating B-cells with consecutive up-regulation of T/B cell ratio was observed at T2 following Leishvaccine immunization (Fig. 4, left upper panels) . On the other hand, up-regulation of T-cells with parallel increase on circulating CD8 + T-cells were the outstanding phenotypic feature at T2 following Leishmune ® vaccination (Fig. 4, right panels) .
Additional analysis of the activation status of Tlymphocyte subsets as well as the B-cell modulator molecule CD32 was also performed following Leishvaccine and Leishmune ® intervention ( 
Up-regulation of CD3 + CD5 +Low CD8 + cells is selectively observed in Leishmune ® vaccines
Recent advances in canine immunological tools including the accessibility of monoclonal antibodies labeled with distinct fluorochromes have allowed the multiparametric analysis of a range of cell subsets that might impact the canine immune response. Herein, we have observed that a singular T-cell subset expressing low density of CD5 + cell surface marker, but an overall unaltered expression of CD3 could be identified following double labeled staining protocol. Additionally, we have characterize this cell population and characterized that all CD5 +Low cells are indeed CD8 + T-cells but not CD4 + T-cells (Fig. 6 , dot plot charts). Aiming to characterize the role of these cells we have followed their frequency in the canine peripheral blood after Leishvaccine 
Discussion
The canine visceral leishmaniasis is currently expanding markedly worldwide, mainly in Brazil, where the typical rural outline has shifted recently toward a progressive urbanization. In endemic areas in Brazil, the prevalence of CVL reported ranges from 5 to 35% [25] . This large prevalence besides the fact that both asymptomatic and symptomatic dogs are equally infectious to the vectors, mainly due to the intense cutaneous parasitism observed in these animals, one of the current strategy for managing the disease includes the detection and elimination of seropositive dogs [1, 26] . However, the selective elimination of seropositive dogs has been pointed an expensive and drastic tool difficult to be implemented with a major impact in the general society [27, 28] . Thus, it has been considered that the implementation of chemotherapeutic procedures as well the use of a protective vaccine against L. (L.) infantum chagasi would represent the most effective alternative to control CVL spreading. Most studies focusing of therapeutic strategies have failed to achieve a consistent parasitological cure in CVL [29, 30] . All these features pointed to immunoprofilaxis as a promising alternative for CVL prevention [15] . Several studies have reported the potential of different Leishmania antigens to trigger immunoprotective mechanisms against CVL. The use of whole L. amazonensis, formerly named Leishvaccine [31] and L. braziliensis antigens [19] as well purified L. donovani antigens [9] , currently available as Leishmune ® have been proposed as a first and second-generation vaccine candidate for CVL, respectively. Most studies, including clinical trials with vaccine candidates, specially Leishvaccine or Leishmune ® , suggested their potent capacity to prevent L. (L.) infantum chagasi infection in dogs [12, 13, 19, 31] . Considering the importance of a vaccine for the control of CVL and the lack of studies regarding the cellular and molecular basis underlying the effectiveness of vaccination, the present work attempted to perform a detailed longitudinal phenotypic analysis of the innate and adaptive compartment of canine peripheral blood as a pre-requisite to understand the immunological mechanisms related to immunogenicity elicited by Leishvaccine or Leishmune ® . Our results showed that interventions with either Leishvaccine or Leishmune ® vaccine were accompanied by distinct profiles regarding the innate immune compartment. While Leishvaccine induced early phenotypic changes in neutrophils and eosinophils with late involvement of monocytes, Leishmune ® induced early and persistent phenotypic changes on neutrophils and monocytes, without alteration in eosinophil activation status. In this study, we have assumed that the increased percentage of MHCI + and MHCII + cells usually refer to an activation event, with the up-regulation of MHCI and MHCII reflecting higher ability of interaction with CD8 + T-cells and CD4 + T-cells, respectively. Therefore, our findings highlighting the downregulation of MHCI in neutrophils and monocytes besides the up-regulation of MHCII in neutrophils may reflect that following Leishvaccine and Leishmune ® vaccination, the neutrophils and monocytes showed higher ability to interact with CD4 + T-cells. As both immunobiological displayed ability to induce phenotypic changes on both CD4 + and CD8 + T-cells, the activation of CD8 + T-cells may be an event that counts with the involvement of other antigen presenting cells.
The higher frequency of MHCII + neutrophils is in consonance with the lower percentage of CD32 + neutrophils, since CD32 is usually associated with neutrophil activation via immunocomplex (IC) and upon stimulation the CD32/IC pair is internalized, which reflected the lower frequency of CD32 + neutrophils observed following vaccination. Moreover, the lower expression index of CD18 observed in circulating neutrophils may indirectly reflect that the activated neutrophils expressing high CD18 density are It has been proposed that the antigen recognition by the innate immunity cells may involve multiple mechanisms [32] . The reliable detection of antigenic determinants would be more or less complex depending of the antigen molecular heterogeneity [32] . Several recognition strategies have already been proposed. The pattern-recognition strategy is based on the detection of a limited set of conserved molecular patterns (PAMPs) that are unique to the microbial world and invariant among entire classes of pathogens. The targets of the PAMPs are named toll-like receptors (TLRs). There are at least 10 mammalian TLRs expressed by different cell populations. To date, the pattern of TLR expression by human leukocytes demonstrated that neutrophils express TLR1 through TLR10, except TLR3, monocytes express TLR1 through TLR8, except TLR3 whereas eosinophils express TLR1, TLR4, TLR7, TLR9, TLR10 [32] . Recently, Bazzocchi et al. [33] have described the partial sequence of the gene coding for canine TLR-2 and show that TLR2 mRNA is constitutively expressed by canine peripheral blood polymorphonuclear cells. Furthermore, using a cross-reactive anti-human TLR2 antibody, these authors have demonstrated that TLR2 protein is expressed by granulocytes, monocytes, but slightly on lymphocytes, with no specific reference to neutrophils and eosinophils. Interestingly, Becker et al. [34] have demonstrated that Leishmania LPG is able to bind to TLR2 and activate the innate immune system and thereby increasing the effective destruction of the parasite, suggesting that TLR2 pathway may represent a relevant loop to trigger anti-Leishmania protective immunity.
In general, TLR ligands have been shown to be excellent vaccine adjuvants in animal studies, promoting development of robust antigen-specific humoral and cellular responses, including cytotoxic T-cell responses [35] . Thus, their clinical potential as vaccine adjuvants has been considered by a number of laboratories. The use of TLR4 and TLR9 agonists, ligands for TLR3, TLR5 and TLR7/8 are currently being investigated in phase 1 and 2 for human vaccine trials against several pathogens [35] . In this context, it has been demonstrated that BCG is able to trigger TLR2 and TLR4 stimulatory action [36] . It is possible that besides the complex antigen formulation the ability of BCG to trigger TLR2 and TLR4 may count to the broader spectrum of innate immunity activation observed following Leishvaccine immunization. However, it is important to mention that although the engagement of TLR signaling pathways is a promising mechanism for boosting vaccine responses, questions of efficacy, feasibility and safety remain the subject of active investigation.
Regardless of the scarcity of information concerning the TLRs expression by canine peripheral blood cells as wells as the interaction between Leishmania antigens with canine TLRs, herein, we speculate that the FML, similarly to LPG is most likely to interact with innate immunity cells throughout TLR2 and therefore selectively stimulate neutrophils and monocytes, but not eosinophils. On the other hand, the complex antigenic nature in Leishvaccine would lead to an interaction with a wide range of TLRs and thus trigger the activation of several leukocyte subsets within the innate immune compartment, with involvement of neutrophils, monocytes and also eosinophils. Its is important to mention that despite the distinct profile triggered by Leishvaccine and Leishmune ® vaccines, both immunobiologicals are capable to stimulate relevant innate immunity cells involved in leshmanicidal activities, such as neutrophils and monocytes, that enable them to elicit a protective immune response against Leishmania infection.
Evidences are being accumulated, suggesting that the innate immune response plays a pivotal role during host resistance against intracellular parasitic infections. This response would act both in controlling pathogen growth during the early stages of infection as well as in driving the cytokine microenvironment in which parasite-specific T-cells are primed [37, 38] .
The activation of phagocytes, the main targets of Leishmania, represents one of the first events linked to the innate immune response to intracellular infection [39, 40] . Upon their activation, neutrophils and monocytes are recruited to inflammatory foci where secrete cytokines, manly IL-12. It has a very important role in stimulating cytotoxicity and IFN-␥ production by NK cells as well as on the development of specific type 1 T-cell-mediated immunity [39, 40] . This microenvironment up regulates the anti-Leismania activity, increasing the phagocytosis and parasite killing through mechanisms such as those related to oxidative burst [41, 42] . Rousseau et al. [43] showed that during the early phase of the infection, neutrophils play an important role in controlling L. infantum burden in the spleen. Furthermore, in L donovani-infected C57BL/6 mice, the depletion of the neutrophils induced an important enhancement of parasite growth in both liver and spleen [44] . Indeed, these data associated with our results reinforce the hypothesis that the involvement of the innate immune, elicited by both vaccines, could be important in the development of the protective immune response during Leishmania challenge.
Although there is a consensus that the phagocytic cells are crucial to Leishmania elimination and infection resolution, data from experimental models have suggested that the effective and consistent activation of phagocytes require an effective adaptive cellular immune response [45] . Furthermore, it is relevant point out that the adaptive cell memory following vaccination is important to successful vaccination. Aiming to evaluate the involvement of the adaptive immunity compartment, we have further focused on the changes in the phenotypic profile of circulation T and B-cells following Leishvaccine and Leishmune ® vaccination. Our major findings showed that while the Leishvaccine triggered a mixed immunological profile, inducing phenotypic changes in both T and B-lymphocytes, the Leishmune ® prompted a selective pattern on cellular adaptive immune response, selectively linked with T-cell activation.
In fact, our data demonstrated that Leishvaccine elicited a consecutive activation of T-cells and B-lymphocytes, with early activation of CD4 + T-cells (CD4 + MHCII + ) and a later activation of B-cells (CD32 in B-cells) and CD8 + T-cells (CD8 + CD18 + ). It has been proposed by Reis et al. [46] that sustained T-cell compartment in the peripheral blood associated with higher activation status of circulating lymphocytes, as demonstrated by higher expression of MHCII is an important event underlying the protective immune response during ongoing asymptomatic CVL. In fact, Cobbold & Metcalfe [21] developed a pioneer investigation regarding the MHCII molecule expression by canine cells. These authors observed that, in contrast with other species, all canine circulating lymphocytes constitutively express the MHCII molecule. It has been proposed that increased expression of MHCII may reflect an antigenic priming-related immunological event [21] . The increased MHCII expression on CD4
+ T-cells following Leishvaccine immunization might reflect their increased ability of antigen presentation leading to effective activity of the immune system supporting the hypothesis that these cells are prone to be primed by Leishmania antigens and may contribute to mount a vigorous protective immune response. These findings are in agreement with those reports that the activation of CD4 + T-lymphocytes is essential for the establishment of the immunological network needed to trigger an effective cellular and humoral immune response to protein antigen, referred as T-dependent antigens [47] . The outstanding increase in the CD18 expression by CD8 + T-cells at T2 following vaccination is the major phenotypic features that indicate the ability of both immunobiological to trigger CD8 + T-cells, and therefore the major finding that support their use as high-quality immunogenic device against CVL. We believe that the down-regulation of MHCII observed in CD4 + and CD8 + T-cells at T3 after Leishvaccine and Leishmune ® vaccination may represent a compensatory immunoregulation mechanism that is triggered to overcome the immune response following antigenic booster. Despite no references concerning the role of canine CD32 molecule, data provide for experimental model as well as investigations in humans have already demonstrated that the downregulation of CD32 expression by B-cells may be associated with an enhanced immunoglobulin synthesis [48] . These data are in agreement with our results that showed decrease in the percentage of CD19 + CD32 + cells, beside higher levels of IgG (data not shown). Further, it has been demonstrated that the level of expression of CD32 on human B cells is not uniform, but depended on activation status [49] . Moreover, TLRs signals can be delivered to B cells directly [50] and as previously discussed would represent a potential mechanism elicited by the whole Leishmania antigenic nature in Leishvaccine. On the other hand, the Leishmune ® led to a preferential involvement of CD8 + T-cells, with no phenotypic changes on circulating Blymphocytes, suggested a possible activation of a selective pathway of cooperation between antigen-presenting cells (APCs) and cytotoxic T-cells.
In a innovative flow cytometric platform analysis for canine cell surface markers, we have performed a dual label protocol and described for the first time, that the dogs presented in their peripheral blood two distinct T-cell subsets based on the differential density of CD5 expression by CD3 + named ''direct'' and ''cross-priming'' pathways [51] . Crosspresentation of exogenous antigens in the context of MHCI molecules has recently attracted a lot of research interest because it may prove crucial for vaccine development. This alternative pathway has been implicated in priming CD8 + Tcell responses to pathogens in vivo. In cross-presentation, the internalized antigens can be processed through diverse intracellular routes [51] . Further studies are currently under investigation in our laboratory to further characterize the functional aspects of these CD3 + CD5 +Low CD8 + T-cells, major focusing on their cytokine profile. Recently, studies have focused on the role of CD8 + T-cells and their relevance in the protective mechanisms during ongoing CVL as well as in the vaccine design against CVL [52, 53] . It is important to highlight that in CVL CD8 + T-cells have been associated with protection and asymptomatic disease [46, 52] . Indeed, it has been shown that CD8 + T-cells are crucial in controlling the primary Leishmania infection by shifting the early Type 2 toward a Type 1 immune response [54, 55, 56] . Moreover, Pinelli et al. [52] postulated that besides cytokine production, it is also possible that CD8 + T-cells participate in the control of Leishmania through cytotoxic mechanisms that eliminate infected macrophages. Therefore, both mechanisms, including the production of IFN-␥ and the destruction of the parasitized host cells by Leishmania-specific T-cells play a pivotal role in resistance to visceral leishmaniasis. The ability of CD8 + T-cells to participate in protective mechanism have been also reported in experimental models for cutaneous L. major leishmaniasis, with the demonstration that CD8
+ T-cells participate in the control of Leishmania throughout IFN-␥ production as well as by up-regulating of IFN-␥ production by CD4 + T-cells [57, 58] . These authors suggested a cross-talk between these two T-cell subsets [57, 58] .
Besides the molecular nature of vaccinal antigen, another interesting approach usually required during the development of first and second-generation vaccines is the search for more potent vaccine adjuvants [59, 60] . Vaccines require optimal adjuvants including immunopotentiator and delivery systems to offer long-term protection from infectious diseases in animals and man. Initially, it was believed that adjuvants are responsible for promoting strong and sustainable antibody responses. Now it has been shown that adjuvants influence the isotype and avidity of antibody and also affect the properties of cell-mediated immunity. Saponin and BCG based adjuvants have the ability to stimulate the cell mediated immune system as well as to enhance antibody production and have the advantage that only a low dose is needed for adjuvant activity [59, 61, 62] . These can be used to improve the immune response to vaccine antigens for several different purposes, including: (1) increase of the immunogenicity of purified antigens; (2) enhancement of the speed and duration of the immune response; (3) modulation of antibody avidity and specificity; (4) stimulation of cell mediated immunity and others [60] .
Herein, we have found that Leishvaccine led to significant changes in the activation status of innate and adaptive immunity cells, characterizing a broader spectrum of immunogenicity. We hypothesized that the BCG-based adjuvant associated with the complex whole crude L. amazonensis antigen formulation used in Leishvaccine could potentiate the establishment of a mixed type of immune response. On the other hand, the saponin-based adjuvant used in Leishmune ® would prompt a selective cellular immune response as previously reported [63] . These data are in agreement with our results that showed a preferentially involvement of phagocytes and CD8 + T-cells in Leishmune ® vaccines. It is likely to speculate that saponin would provide optimal condition for FML uptake by APCs' making it prone to be presented throughout MHCI molecules as proposed in the cross-priming theory [51] . Altogether, our data demonstrated that Leishvaccine and Leishmune ® induced distinct phenotypic changes in the peripheral blood innate and adaptive immunity compartments, with the latter inducing a more selective involvement of the cellular immune response. We believe that this dissimilar activation of immunological events would represent phenomenon directly related with the molecular nature of these vaccines besides the distinct adjuvants employed. However, it is important to emphasize that both immunobiologicals are able to activate phagocytes and CD8 + T-cells and therefore could be considered priority vaccines with a high-quality immunogenic potential against CVL.
